Thermo Fisher Scientific Inc, a company that serves science, announced on Monday that it has launched the Thermo Scientific Hypulse Surface Analysis System, a next-generation instrument for X-ray photoelectron spectroscopy (XPS) depth-profiling.
Designed to accelerate materials research, the Hypulse system enables deeper, more accurate analysis of surfaces to support industries from energy storage and fire protection to medical implants. In healthcare applications, the technology could inform the development of coatings that improve biocompatibility, durability and infection resistance.
The system is distinguished by its use of femtosecond laser technology for material removal, allowing faster data collection, greater depth penetration and improved preservation of sample accuracy.
Thermo Fisher said the Hypulse platform represents a step forward in creating better materials and enhancing industrial applications, advancing its mission to enable customers to make the world healthier, cleaner and safer.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA